PFG Investments LLC Has $2.24 Million Stake in Verona Pharma PLC American Depositary Share $VRNA

PFG Investments LLC lowered its holdings in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) by 8.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,700 shares of the company’s stock after selling 2,300 shares during the period. PFG Investments LLC’s holdings in Verona Pharma PLC American Depositary Share were worth $2,242,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. GAMMA Investing LLC grew its position in Verona Pharma PLC American Depositary Share by 5.6% in the second quarter. GAMMA Investing LLC now owns 1,940 shares of the company’s stock valued at $183,000 after purchasing an additional 103 shares in the last quarter. Geneos Wealth Management Inc. grew its position in Verona Pharma PLC American Depositary Share by 44.2% in the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company’s stock valued at $40,000 after purchasing an additional 193 shares in the last quarter. NBC Securities Inc. bought a new position in Verona Pharma PLC American Depositary Share in the first quarter valued at $34,000. Advisors Preferred LLC grew its position in Verona Pharma PLC American Depositary Share by 65.4% in the first quarter. Advisors Preferred LLC now owns 1,599 shares of the company’s stock valued at $94,000 after purchasing an additional 632 shares in the last quarter. Finally, Townsquare Capital LLC grew its position in Verona Pharma PLC American Depositary Share by 4.1% in the first quarter. Townsquare Capital LLC now owns 18,688 shares of the company’s stock valued at $1,187,000 after purchasing an additional 730 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

Insiders Place Their Bets

In other Verona Pharma PLC American Depositary Share news, Director Vikas Sinha sold 4,328 shares of Verona Pharma PLC American Depositary Share stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $13.14, for a total value of $56,869.92. Following the completion of the sale, the director owned 94,112 shares in the company, valued at $1,236,631.68. The trade was a 4.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David R. Ebsworth sold 1,904 shares of Verona Pharma PLC American Depositary Share stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $25,018.56. Following the completion of the sale, the director owned 880,499 shares of the company’s stock, valued at $11,569,756.86. This trade represents a 0.22% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 540,584 shares of company stock worth $7,103,274. 4.80% of the stock is currently owned by insiders.

Verona Pharma PLC American Depositary Share Stock Performance

Shares of VRNA stock opened at $106.82 on Thursday. The company has a market capitalization of $9.21 billion, a price-to-earnings ratio of -107.90 and a beta of 0.05. The company has a debt-to-equity ratio of 0.87, a quick ratio of 10.54 and a current ratio of 10.71. The company has a 50-day simple moving average of $105.84 and a 200 day simple moving average of $87.11. Verona Pharma PLC American Depositary Share has a 52 week low of $28.44 and a 52 week high of $106.85.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. The business had revenue of $103.14 million during the quarter, compared to the consensus estimate of $90.41 million. On average, sell-side analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on VRNA. HC Wainwright restated a “neutral” rating and set a $107.00 price objective (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, July 14th. Piper Sandler lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. Wolfe Research lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 10th. Canaccord Genuity Group lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and set a $107.00 price objective on the stock. in a research note on Wednesday, July 9th. Finally, Cantor Fitzgerald boosted their price objective on shares of Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 11th. Two analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $109.00.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.